National Comprehensive Cancer Network (NCCN) guidelines was strongly recommend EGFR testing in NSCLC, and TKIs are also recommended as a first line treatment for NSCLC patients with sensitive EGFR mutations15. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.